Trans fat feeding results in higher serum alanine aminotransferase and increased insulin resistance compared with a standard murine high-fat diet.
Diets high in trans fats are associated with an increased risk of cardiovascular disease and components of the metabolic syndrome. The influence of these toxic fatty acids on the development of nonalcoholic fatty liver disease has not been significantly examined. Therefore, we sought to compare the effect of a murine diet high in trans fat to a standard high-fat diet that is devoid of trans fats but high in saturated fats. Male AKR/J mice were fed a calorically identical trans fat diet or standard high-fat diet for 10 days, 4 wk, and 8 wk. Serum alanine aminotransferase (ALT), lipid, insulin, and leptin levels were determined and the quantitative insulin-sensitivity check index (QUICKI) was calculated as a measure of insulin resistance. Additionally, hepatic triglyceride content and gene expression of several proinflammatory genes were assessed. By 8 wk, trans fat-fed mice exhibited higher ALT values than standard high-fat-fed mice (126 +/- 16 vs. 71 +/- 7 U/l, P < 0.02) despite similar hepatic triglyceride content at each time point. Trans fat-fed mice also had increased insulin resistance compared with high-fat-fed mice at 4 and 8 wk with significantly higher insulin levels and lower QUICKI values. Additionally, hepatic interleukin-1beta (IL-1beta) gene expression was 3.6-fold higher at 4 wk (P < 0.05) and 5-fold higher at 8 wk (P < 0.05) in trans fat-fed mice compared with standard high-fat-fed mice. Trans fat feeding results in higher ALT values, increased insulin resistance, and elevated IL-1beta levels compared with standard high-fat feeding.
Koppe
Sean W P
SW
Division of Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. s-koppe@northwestern.edu
Elias
Marc
M
Moseley
Richard H
RH
Green
Richard M
RM
D000410:Alanine Transaminase / Q000097:blood*; D000818:Animals; D002784:Cholesterol / Q000097:blood; D004041:Dietary Fats / Q000633:toxicity*; D005234:Fatty Liver / Q000201:enzymology / Q000209:etiology* / Q000503:physiopathology; D018836:Inflammation Mediators / Q000378:metabolism; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D053583:Interleukin-1beta / Q000378:metabolism; D020738:Leptin / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000503:physiopathology; D008297:Male; D051379:Mice; D019301:Oleic Acid / Q000633:toxicity; D009829:Oleic Acids; D012720:Severity of Illness Index; D013997:Time Factors; D044242:Trans Fatty Acids / Q000633:toxicity*; D014280:Triglycerides / Q000378:metabolism; D015854:Up-Regulation; D015430:Weight Gain
D004041:Dietary Fats; D018836:Inflammation Mediators; D007328:Insulin; D053583:Interleukin-1beta; D020738:Leptin; D009829:Oleic Acids; D044242:Trans Fatty Acids; D014280:Triglycerides; D019301:Oleic Acid; C011459:elaidic acid; D002784:Cholesterol; D000410:Alanine Transaminase